Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Sands on the Importance of NGS Testing in Lung Cancer

February 4th 2022

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

RNA-Based NGS Offers the Potential to Identify More Patients With Rare Alterations in NSCLC

February 4th 2022

The field of non–small cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Treatment Selection in mNSCLC without Actionable Genetic Alterations

January 31st 2022

Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.

Making Progress Against the Blood-Brain Barrier

January 31st 2022

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.

EGFR+ Advanced NSCLC: Review of Bevacizumab-Based Combination Therapy

January 31st 2022

Experts review frontline combination approaches with bevacizumab in EGFR+ advanced non–small cell lung cancer.

Regional Approaches to Frontline Treatment for EGFR+ Advanced NSCLC

January 31st 2022

A comprehensive discussion on frontline treatment options for patients with EGFR+ advanced non–small cell lung cancer.

Criteria Used to Diagnose Small Cell Lung Cancer

January 31st 2022

Symptoms and risk factors associated with small cell lung cancer, and recommendations for staging patients with newly diagnosed disease.

Lorlatinib Approved in Europe for ALK+ Advanced NSCLC

January 28th 2022

The European Commission has granted a marketing authorization for lorlatinib for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer who did not receive a prior ALK inhibitor.

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

January 27th 2022

The identification of actionable oncogenetic drivers in patients with non–small cell lung cancer affords clinicians the opportunity to use targeted agents to optimize outcomes.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer

January 26th 2022

Raymond U. Osarogiagbon, MD, FACP, discusses geographic disparities in lung cancer.

Dr. Patel on Optimizing Molecular Testing for EGFR Mutations in Lung Cancer

January 26th 2022

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

Happy Upheavals Are Unveiled in Early-Stage Lung Cancer

January 26th 2022

Although advances in metastatic non–small cell lung cancer treatment have dramatically impacted cancer mortality, the translation of these approaches to earlier-stage NSCLC has just begun to bear fruit.

Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung Cancer

January 25th 2022

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

Resectable NSCLC: Is There a Role for Multidisciplinary Care and Neoadjuvant Therapy?

January 24th 2022

Closing out their discussion on resectable NSCLC, experts review multidisciplinary care strategies and the role of neoadjuvant therapy in patients identified for resection.

Global Perspectives on Routine Molecular Testing in Postoperative NSCLC

January 24th 2022

In light of evolving treatment options for resectable non–small cell lung cancer, panelists discuss biomarker testing to guide adjuvant therapy in the postoperative setting.

FDA Accepts sBLA for Cemiplimab Plus Chemo in Frontline Advanced NSCLC

January 19th 2022

The FDA has accepted for review a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer.

Clinical Pearls and the Future of LEMS

January 19th 2022

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

January 18th 2022

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Patel Breaks Down the Meaning of Molecular Testing in Lung Cancer

January 18th 2022

Paying particular attention to the specific type of gene mutation on a molecular testing report is critical in an era of increasing genomic complexity in non–small cell lung cancer.